Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data The PRISMA-IPD Statement

被引:1518
作者
Stewart, Lesley A. [1 ]
Clarke, Mike [2 ]
Rovers, Maroeska [3 ]
Riley, Richard D. [4 ,5 ]
Simmonds, Mark [1 ]
Stewart, Gavin [1 ,6 ]
Tierney, Jayne F. [7 ]
机构
[1] Univ York, Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England
[2] Queens Univ Belfast, All Ireland Hub Trials Methodol Res, Belfast, Antrim, North Ireland
[3] Radboudumc, Radbound Inst Hlth Sci, Nijmegen, Netherlands
[4] Keele Univ, Res Inst Primary Care & Hlth Sci, Keele ST5 5BG, Staffs, England
[5] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham, W Midlands, England
[6] Newcastle Univ, Ctr Rural Econ, Sch Agr Food & Rural Dev, Newcastle Upon Tyne, Tyne & Wear, England
[7] UCL, MRC Clin Trials Unit, London, England
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2015年 / 313卷 / 16期
关键词
PATIENT DATA; PREDICTION MODELS; RISK; MORTALITY; OUTCOMES; TRIALS;
D O I
10.1001/jama.2015.3656
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Systematic reviews and meta-analyses of individual participant data (IPD) aim to collect, check, and reanalyze individual-level data from all studies addressing a particular research question and are therefore considered a gold standard approach to evidence synthesis. They are likely to be used with increasing frequency as current initiatives to share clinical trial data gain momentum and may be particularly important in reviewing controversial therapeutic areas. OBJECTIVE To develop PRISMA-IPD as a stand-alone extension to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement, tailored to the specific requirements of reporting systematic reviews and meta-analyses of IPD. Although developed primarily for reviews of randomized trials, many items will apply in other contexts, including reviews of diagnosis and prognosis. DESIGN Development of PRISMA-IPD followed the EQUATOR Network framework guidance and used the existing standard PRISMA Statement as a starting point to draft additional relevant material. A web-based survey informed discussion at an international workshop that included researchers, clinicians, methodologists experienced in conducting systematic reviews and meta-analyses of IPD, and journal editors. The statement was drafted and iterative refinements were made by the project, advisory, and development groups. The PRISMA-IPD Development Group reached agreement on the PRISMA-IPD checklist and flow diagram by consensus. FINDINGS Compared with standard PRISMA, the PRISMA-IPD checklist includes 3 new items that address (1) methods of checking the integrity of the IPD (such as pattern of randomization, data consistency, baseline imbalance, and missing data), (2) reporting any important issues that emerge, and (3) exploring variation (such as whether certain types of individual benefit more from the intervention than others). A further additional item was created by reorganization of standard PRISMA items relating to interpreting results. Wording was modified in 23 items to reflect the IPD approach. CONCLUSIONS AND RELEVANCE PRISMA-IPD provides guidelines for reporting systematic reviews and meta-analyses of IPD.
引用
收藏
页码:1657 / 1665
页数:9
相关论文
共 35 条
  • [1] Individual participant data meta-analyses should not ignore clustering
    Abo-Zaid, Ghada
    Guo, Boliang
    Deeks, Jonathan J.
    Debray, Thomas P. A.
    Steyerberg, Ewout W.
    Moons, Karel G. M.
    Riley, Richard David
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2013, 66 (08) : 865 - 873
  • [2] Individual participant data meta-analysis of prognostic factor studies: state of the art?
    Abo-Zaid, Ghada
    Sauerbrei, Willi
    Riley, Richard D.
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2012, 12
  • [3] Developing and validating risk prediction models in an individual participant data meta-analysis
    Ahmed, Ikhlaaq
    Debray, Thomas P. A.
    Moons, Karel G. M.
    Riley, Richard D.
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2014, 14
  • [4] Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey
    Ahmed, Ikhlaaq
    Sutton, Alexander J.
    Riley, Richard D.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
  • [5] ALBERTI W, 1995, BRIT MED J, V311, P899
  • [6] [Anonymous], 1988, NEW ENGL J MED, V319, P1681
  • [7] Effects of NXY-059 in experimental stroke: an individual animal meta-analysis
    Bath, P. M. W.
    Gray, L. J.
    Bath, A. J. G.
    Buchan, A.
    Miyata, T.
    Green, A. R.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (07) : 1157 - 1171
  • [8] PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts
    Beller, Elaine M.
    Glasziou, Paul P.
    Altman, Douglas G.
    Hopewell, Sally
    Bastian, Hilda
    Chalmers, Iain
    Gotzsche, Peter C.
    Lasserson, Toby
    Tovey, David
    [J]. PLOS MEDICINE, 2013, 10 (04)
  • [9] Berlin JA, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P35, DOI 10.1002/0470870168.ch3
  • [10] Methods for meta-analysis of individual participant data from Mendelian randomisation studies with binary outcomes
    Burgess, Stephen
    Thompson, Simon G.
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2016, 25 (01) : 272 - 293